



## **APPENDIX B: PENDING CLAIMS**

1. (Amended) An endometriosis or infertility treating pharmaceutical composition comprising:
  - (i) a therapeutically effective amount of a  $\beta$ -adrenergic agonist, and
  - (ii) a pharmaceutically acceptable bioadhesive carrier.
2. The composition of claim 1 wherein the  $\beta$ -adrenergic agonist is terbutaline.
3. The composition of claim 2 wherein the bioadhesive carrier is a cross-linked water insoluble but water swellable polycarboxylic acid polymer.
4. (Amended) The composition of claim 3, wherein the concentration of terbutaline is about 0.1% to about 0.4% weight/weight.
5. The composition of claim 4, wherein the polymer is polycarbophil.
6. (Amended) An endometriosis or infertility treating pharmaceutical composition comprising a therapeutically effective amount of a  $\beta$ -adrenergic agonist.
7. (Amended) The composition of claim 6, wherein the  $\beta$ -adrenergic agonist is terbutaline, and the composition is formulated to be administered in a dosage that delivers about 1 mg. to about 8 mg. of terbutaline.
8. The composition of claim 7 wherein the composition further comprises a bioadhesive, water insoluble but water swellable, cross-linked polycarboxylic acid polymer.
9. The composition of claim 8, wherein the polymer is polycarbophil.
10. (Amended) The composition of claim 9 formulated to be administered in a dosage that delivers about 2 mg to about 4 mg of terbutaline.
- 11-12. canceled

13. A method of treating endometriosis or infertility, or of improving fertility, comprising administering a therapeutically effective amount of a composition comprising a  $\beta$ -adrenergic agonist and a pharmaceutically acceptable bioadhesive carrier locally to the vaginal mucosa of a patient in need thereof.

14. (Amended) The method of claim 13, wherein the  $\beta$ -adrenergic agonist is terbutaline, and the composition is formulated to be administered in a dosage that delivers about 1 mg. to about 8 mg. of terbutaline.

15. (Amended) The method of claim 14, wherein the composition is administered in a dosage that delivers about 2 mg to about 4 mg of terbutaline.

16. A method of treating endometriosis or infertility, or of improving fertility, comprising administering a therapeutically effective amount of a composition comprising a  $\beta$ -adrenergic agonist and a pharmaceutically acceptable bioadhesive carrier locally to the vaginal mucosa of a patient in need thereof, while avoiding detrimental blood levels of said a  $\beta$ -adrenergic agonist.

17. The method of claim 16 wherein the  $\beta$ -adrenergic agonist is terbutaline.

18. The method of claim 17 wherein the bioadhesive carrier comprises a cross-linked water insoluble but water swellable polycarboxylic acid polymer.

19. The method of claim 18, wherein the polymer is polycarbophil.

20. (Amended) The method of claim 15, wherein the composition is administered every 12 to 96 hours.

21. (Amended) The method of claim 15, wherein the composition is administered twice weekly.

22. (Twice amended) The method of claim 15, wherein the composition is administered in the form of a tablet.

23-35. canceled

36. (New) A pharmaceutical composition for treating endometriosis comprising:

- (i) terbutaline at a concentration of about 0.1% to about 0.4% weight/weight;
- and
- (ii) polycarbophil.

37. (New) A pharmaceutical composition for treating infertility or improving fertility comprising:

- (i) terbutaline at a concentration of about 0.1% to about 0.4% weight/weight;
- and
- (ii) polycarbophil.